30-day average of 21 articles · scale −100 to +100
Across 21 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of MetLife news is Somewhat Bullish (+40)
on a scale from −100 to +100.
That is about the same as the previous 30 days (+44).
💸 The company returned approximately $1 billion to shareholders via buybacks and dividends in Q3.
🏦 Net income surged 187% year-over-year to $2.4 billion, or $3.67 per share.
🎯 MetLife remains on track to meet its full-year free cash flow and direct expense ratio targets.
💼 CEO Michel Khalaf reaffirmed confidence in the New Frontier strategy and execution discipline.
📉 Holding-company cash and liquid assets stood at $3.4 billion, within management's target range.
🚀 Broad-based operating momentum supports the case for resilient earnings across divisions.
📈 Bullish signals
📈MetLife reported record Q3 adjusted EPS of $2.85 excluding notable items, a 22% increase from the prior-year quarter and the highest in company history.
💰Revenue increased 12% to $14.1 billion with growth spanning all six business segments, demonstrating broad-based momentum.
📊Adjusted return on equity reached 19.6% excluding notable items, reflecting strong capital efficiency.
💸The company returned approximately $1 billion to shareholders through buybacks and dividends, signaling confidence in its financial position.
🏦Net income surged 187% year-over-year to $2.4 billion, driven by higher variable investment income and favorable underwriting.
🎯MetLife remains on track to meet its full-year free cash flow and direct expense ratio targets, ensuring disciplined capital management.
💼CEO Michel Khalaf reaffirmed confidence in the New Frontier strategy, citing stronger underwriting and volume growth as key drivers.
Article
MetLife Inc. reported record third-quarter adjusted earnings per share of $2.85, excluding notable items, representing a 22% increase from the prior-year quarter. This achievement marks the highest quarterly level in the company's history, driven by broad-based growth across all six business segments. Revenue increased by 12% to $14.1 billion, supported by higher variable investment income, volume growth, and favorable underwriting results.
The company reported net income of $2.4 billion, or $3.67 per share, which was up 187% year-over-year. Adjusted return on equity reached 19.6% excluding notable items, while MetLife confirmed it remains on track to meet its full-year targets for free cash flow and direct expense ratios. Holding-company cash and liquid assets stood at $3.4 billion at quarter-end, aligning with management's target range.
MetLife returned approximately $1 billion to shareholders through share repurchases and common stock dividends during the quarter, highlighting a continued focus on capital returns alongside reinvestment for growth. CEO Michel Khalaf emphasized that the results demonstrate the strength of the New Frontier strategy and the discipline of its execution, citing stronger underwriting and investment returns as key drivers.
The earnings release indicates broad operating momentum rather than growth concentrated in a single division, supporting the case for resilient earnings. MetLife stock traded at 92.45 euros on November 12, 2026, reflecting positive market sentiment following the announcement of these robust financial results and strategic confidence.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
The article compares Prudential Financial and MetLife as dividend-focused investment options for retirees, highlighting a significant yield gap. Prudential Financial offers a 5.0% yield with quarterly dividends of $1.40 per share, while MetLife yields 2.5% at $2.25 annually. Both companies have demonstrated consistent dividend growth over the past five years, with Prudential growing at 4.2% and MetLife at 4.3% from fiscal 2020 to 2025.
Prudential Financial reported strong second-quarter results with after-tax adjusted operating income rising to $1.44 billion, driven by record earnings in its Group Insurance segment. The company maintains a payout ratio of 37% of normalized EPS, which is expected to rise slightly to 39% in fiscal 2026. CEO Andrew Sullivan has committed to cost-saving measures targeting $750 million in pretax benefits by the end of 2028.
MetLife focuses more on share repurchases than dividends, returning over $1.1 billion in the second quarter with approximately $700 million allocated to buybacks. The company reported a 20% increase in adjusted EPS to $2.43 and expects normalized earnings to grow from $8.83 in fiscal 2025 to $10.14 in fiscal 2026, resulting in a comfortable payout ratio of 25%.
The primary risk for Prudential Financial involves its operations in Japan, where a sales suspension is projected to cost between $525 million and $575 million in pretax adjusted operating income for 2026. Management has committed to implementing necessary changes by November 5 to resume sales. MetLife's main risk lies in the potential normalization of favorable underwriting margins within its Group Benefits segment, which could impact future profitability.
📈 MET adjusted EPS grew 20% YoY to $2.43 with Group Benefits up 25%.
💰 MET maintains a 25% covered dividend payout ratio with ample growth room.
🔄 MET prioritized organic growth and allocated over $1.1 billion to buybacks.
⚠️ MET warns favorable underwriting margins in Group Benefits may normalize gradually.
📈 Prudential Financial offers a 5.0% dividend yield compared to MetLife's 2.5%, providing retirees with double the annual income per share.
💰 Both companies have increased their dividends annually by approximately 4.2% to 4.3% over the five-year period from fiscal 2020 to fiscal 2025.
📊 Prudential Financial reported record quarterly earnings in Group Insurance, with after-tax adjusted operating income rising to $1.44 billion in the second quarter.
🛡️ MetLife maintains a highly covered dividend payout ratio of 25% based on fiscal 2025 normalized EPS, leaving ample room for growth.
📉 Prudential Financial faces a specific risk from Japan where a sales suspension is expected to reduce 2026 pretax adjusted operating income by $525 million to $575 million.
🔄 MetLife prioritizes organic growth and share repurchases, allocating over $1.1 billion to buybacks in the second quarter rather than increasing dividends.
📈 MetLife's adjusted EPS grew 20% year-over-year to $2.43 in the second quarter, with Group Benefits earnings up 25%.
🔮 Prudential Financial trades at 8.1x forward earnings, which is right at its five-year average valuation range.
⏳ Management at Prudential has committed to resolving Japan sales issues by November 5 to resume operations and mitigate income loss.
⚠️ MetLife executives warn that favorable underwriting margins in Group Benefits may gradually normalize over time, affecting future profitability.
Bullish Signals
Dividend payout ratio is 25% and expected to drop to 23% in fiscal 2026.
Risk Factors
Underwriting margins normalizing may reduce future profitability.
Prioritizing $700M buybacks over dividend growth increases risk.
Bullish Signals
MetLife maintains a very comfortable dividend payout ratio of 25% based on fiscal 2025 normalized EPS, which is expected to decrease further to 23% on fiscal 2026 consensus estimates.
The company reported strong second-quarter performance with adjusted EPS rising 20% to $2.43, driven by a 25% increase in Group Benefits earnings.
MetLife's normalized earnings are projected to grow from $8.83 in fiscal 2025 to $10.14 in fiscal 2026, providing a solid cushion for its dividend payments.
The company has grown its dividend significantly over the long term, with annual payouts increasing from $1.57 per share in fiscal 2016 to $2.25 in fiscal 2025.
MetLife carries less debt relative to TIKR's measures compared to Prudential Financial, enhancing its financial stability for dividend support.
Risk Factors
MetLife executives expect favorable underwriting margins in Group Benefits to gradually normalize over time, which could reduce future profitability.
The company prioritizes share buybacks over dividend growth, returning approximately $700 million to repurchases in the second quarter instead of increasing payouts.
MetLife Inc. reported strong second-quarter 2026 financial results, with adjusted earnings reaching USD 1.6 billion, representing a 15% increase from the prior-year period. Adjusted earnings per share rose significantly by 20% to USD 2.43, while the company achieved an adjusted return on equity of 17%, hitting the top end of its annual target range between 15% and 17%. These robust operating metrics provided a solid foundation for positive analyst sentiment surrounding the insurer's stock performance.
Following the release of these results, Wells Fargo raised its price target for MetLife stock from USD 109.00 to USD 110.00 on October 12, 2026. This action contributes to a broader trend of positive analyst coverage, with Piper Sandler also maintaining an Overweight rating and a USD 110.00 target following its own upgrade in September. The average 12-month price target across analysts stands at USD 105.06, suggesting continued confidence in the company's valuation despite the stock trading around EUR 89.26.
MetLife also announced a fourth-quarter 2026 dividend of USD 0.5925 per share on October 6, 2026, reinforcing its commitment to capital return to shareholders. The company is scheduled to publish its third-quarter 2026 results after market close on November 4, 2026, with an earnings call following on November 5, 2026. Investors will be watching to see if the demonstrated earnings growth and capital-return program can sustain the higher valuation case supported by recent analyst upgrades.
MetLife Inc., trading under ticker MET on the NYSE, has a market capitalization of USD 63.4 billion as of October 14, 2026. The stock's 52-week range spans from USD 67.33 to USD 101.44, placing the current trading price within a reasonable band relative to its historical volatility. As a major player in the Financials and Insurance sectors, MetLife continues to balance growth initiatives with shareholder returns, supported by consistent operational performance.
📈 MetLife Q2 adjusted earnings rose 15% to USD 1.6 billion.
💰 Adjusted EPS increased 20% to USD 2.43 in Q2 2026.
🎯 MetLife hit its top ROE target of 17% for the year.
💵 Company declared a Q4 dividend of USD 0.5925 per share.
📅 Q3 results will be released after market close on Nov 4.
📈 MetLife reported adjusted earnings of USD 1.6 billion in Q2 2026, up 15% year-over-year.
💰 Adjusted earnings per share increased 20% to USD 2.43 in the second quarter of 2026.
🎯 MetLife achieved an adjusted return on equity of 17%, reaching the top of its annual target range.
📊 Wells Fargo raised its price target for MetLife stock from USD 109.00 to USD 110.00 on October 12, 2026.
🤝 Piper Sandler maintains an Overweight rating with a USD 110.00 target following a September upgrade.
💵 MetLife declared a Q4 2026 dividend of USD 0.5925 per share on October 6, 2026.
📅 The company will release Q3 2026 results after market close on November 4, 2026.
🏢 MetLife trades on the NYSE with a market capitalization of USD 63.4 billion as of October 14, 2026.
📉 The stock's 52-week range is between USD 67.33 and USD 101.44.
🔍 The average 12-month analyst price target stands at USD 105.06 based on prior year ratings.
Bullish Signals
Adjusted earnings rose 15% to USD 1.6B in Q2 2026.
Bullish Signals
MetLife reported adjusted earnings of USD 1.6 billion in Q2 2026, a 15% increase from the prior-year period.
Adjusted earnings per share rose 20% to USD 2.43, demonstrating strong profitability growth.
The company achieved an adjusted return on equity of 17%, hitting the top end of its annual target range.
Wells Fargo raised its price target for MetLife stock from USD 109.00 to USD 110.00 following the earnings release.
Piper Sandler maintains an Overweight rating with a USD 110.00 target, contributing to positive analyst sentiment.
The average 12-month analyst price target stands at USD 105.06, indicating sustained institutional confidence.
MetLife declared a Q4 2026 dividend of USD 0.5925 per share, supporting shareholder returns.
MetLife Inc. (NYSE: MET) is preparing to release its third-quarter 2026 financial results, scheduled for November 4, 2026, following the market close. The company's stock was trading at EUR 89.77 on October 14, 2026, with a market capitalization of USD 64.8 billion as of October 13. MetLife is a major player in the financials sector, specifically focused on life insurance and related financial protection products.
Prior to the upcoming earnings release, MetLife declared a fourth-quarter 2026 common-stock dividend of USD 0.5925 per share on October 6, 2026, with payments scheduled for December 8, 2026. This capital return initiative adds a concrete date to the company's shareholder calendar while market attention shifts toward verifying the operating performance that supports such payouts.
Recent data from MarketBeat indicates a mixed picture for MetLife in the quarter reported on August 5, 2026. While earnings per share of USD 2.43 exceeded the consensus estimate of USD 2.30 by USD 0.13, total revenue rose only 10.5% year over year to USD 13.52 billion, falling significantly short of the USD 19.67 billion estimate cited in the report. Investors will be closely watching the November release to determine if profit strength is broadening beyond the EPS beat.
The upcoming earnings report serves as a critical test for MetLife's business health, specifically regarding whether its revenue generation can match its profitability metrics. The conference call is scheduled for November 5, 2026, from 9:00 a.m. to 10:00 a.m. ET, providing further context on the company's operational trajectory and future outlook.
📅 MetLife releases Q3 2026 results after close on November 4, 2026.
💰 Company declared Q4 2026 dividend of USD 0.5925 per share.
📈 EPS of USD 2.43 beat consensus estimate by USD 0.13.
📉 Revenue of USD 13.52 billion missed the USD 19.67 billion estimate.
🏢 MetLife operates in Financials sector specializing in life insurance products.
📅 MetLife will release third-quarter 2026 results after market close on November 4, 2026, with a conference call scheduled for November 5.
💰 The company declared a fourth-quarter 2026 dividend of USD 0.5925 per share on October 6, payable on December 8, 2026.
📈 Recent quarterly earnings per share of USD 2.43 beat the consensus estimate of USD 2.30 by USD 0.13.
📉 Revenue for the quarter reported on August 5, 2026, was USD 13.52 billion, missing the cited estimate of USD 19.67 billion despite a 10.5% year-over-year rise.
💵 MetLife stock traded at EUR 89.77 on October 14, 2026, with a market capitalization of USD 64.8 billion as of October 13.
🏢 The company operates in the Financials sector, specializing in life insurance and financial protection products.
Bullish Signals
EPS hit $2.43, beating estimates by $0.13.
Declared Q4 2026 dividend of $0.5925/share.
Risk Factors
Revenue of USD 13.52B missed estimate of USD 19.67B.
MetLife posted quarterly earnings per share of USD 2.43 for the quarter reported on August 5, 2026, which exceeded the USD 2.30 consensus estimate by USD 0.13.
The company declared a fourth-quarter 2026 common-stock dividend of USD 0.5925 per share, demonstrating continued commitment to capital returns to shareholders.
Risk Factors
MetLife's quarterly revenue of USD 13.52 billion was significantly below the cited estimate of USD 19.67 billion, indicating a potential disconnect between profitability and top-line growth.
The substantial gap between actual revenue (USD 13.52 billion) and estimated revenue (USD 19.67 billion) suggests that the company's broader operating performance may be under pressure despite the earnings-per-share beat.
MetLife Inc. (MET) traded at USD 99.45 on the NYSE on October 12, 2026, maintaining a market capitalization of USD 64.0 billion. The stock price sits near the upper end of its 52-week range between USD 67.33 and USD 100.93, though session volume was notably low at 276,263 shares compared to an average daily volume of over 3.3 million.
The company operates as a large insurance platform with significant exposure to employee benefits, retirement solutions, annuities, asset management, and international operations. Analysts view the stock at a P/E ratio of approximately 19.09, reflecting its valuation relative to earnings in the financial services sector.
Market sentiment saw a slight adjustment on October 7, 2026, when Mizuho Securities lowered its price target for MetLife from USD 112.00 to USD 109.00 while retaining an Outperform rating. The company is scheduled to release its third-quarter 2026 financial results on November 4, 2026, followed by an earnings call on November 5.
MetLife faces a modest headwind from the analyst target reduction, yet the stock remains positioned near its yearly high. Investors will be watching the upcoming Q3 earnings report for further guidance on the insurer's performance in benefits and international markets.
📊 MetLife traded at USD 99.45 with a USD 64 billion market cap.
📉 Mizuho lowered MetLife price target from USD 112 to USD 109.
📅 MetLife scheduled to publish Q3 2026 results on November 4, 2026.
🏦 MetLife operates in Financials/Insurance with a P/E ratio of 19.09.
📈 Stock trades near USD 100.93 high despite lower trading volume.
📊 MetLife traded at USD 99.45 on October 12, 2026, with a market cap of USD 64.0 billion.
📉 Mizuho lowered its price target for MetLife from USD 112.00 to USD 109.00 on October 7, 2026.
📅 MetLife is scheduled to publish third-quarter 2026 results on November 4, 2026.
🏦 The company operates in the Financials/Insurance sector with a P/E ratio of 19.09.
📈 The stock trades near its 52-week high of USD 100.93 despite lower-than-average trading volume.
💼 MetLife's business includes employee benefits, retirement solutions, annuities, and asset management.
Bullish Signals
Trading near 52-week high at USD 99.45.
Mizuho retains Outperform rating for long-term prospects.
Risk Factors
Mizuho lowered price target from USD 112.00 to USD 109.00.
Trading volume on Oct 12 was 276,263 vs 3.3M average.
Bullish Signals
MetLife is trading near the upper end of its 52-week range at USD 99.45, indicating strong relative performance compared to its yearly low of USD 67.33.
Mizuho Securities retains an Outperform rating on MetLife despite lowering the price target, signaling continued confidence in the company's long-term prospects.
Risk Factors
Mizuho lowered its price target for MetLife from USD 112.00 to USD 109.00, suggesting a slight reduction in near-term upside expectations.
Trading volume on October 12 was significantly below average at 276,263 shares versus a typical daily average of over 3.3 million shares.
Mizuho Securities has lowered its price target for MetLife Inc. (MET) from USD 112 to USD 109, maintaining an Outperform rating. This revision reflects a cautious outlook despite the company's recent financial performance, with the new target remaining above the current trading price of approximately EUR 87.89 as of October 9, 2026.
MetLife reported strong second-quarter results in 2026, with adjusted earnings per share rising 20% year-over-year to USD 2.43 and total adjusted earnings increasing 15% to USD 1.6 billion. The company achieved an adjusted return on equity of 17%, hitting the top end of its annual target range, while also declaring a fourth-quarter dividend of USD 0.59 per share.
Management noted that favorable group-life mortality ratios are expected to normalize after a recent quarterly figure of 79%, which was below the company's 2026 target range of 83% to 88%. Investors will watch the upcoming third-quarter earnings release on November 4, 2026, for further confirmation of the company's trajectory and capital-return strategy.
MetLife currently holds a market capitalization of USD 63.4 billion and trades within a 52-week range of USD 67.33 to USD 100.93. The stock is listed on the NYSE in the Financial Services sector, specifically Life Insurance, and continues to be a key focus for analysts monitoring its mortality trends and capital management.
📉 Mizuho cuts MetLife price target to USD 109 while retaining Outperform rating.
📈 Q2 adjusted EPS rose 20% year-over-year to USD 2.43.
💰 Adjusted earnings grew 15% to USD 1.6 billion with 17% ROE.
📅 Q4 dividend of USD 0.59 payable December 8, 2026.
⚠️ Mortality ratios expected to normalize after recent quarterly low of 79%.
📉 Mizuho cuts MetLife price target from USD 112.00 to USD 109.00 while retaining an Outperform rating.
📈 MetLife reported Q2 2026 adjusted EPS of USD 2.43, representing a 20% year-over-year increase.
💰 Adjusted earnings grew 15% to USD 1.6 billion with an adjusted return on equity of 17%.
📅 MetLife declared a Q4 dividend of USD 0.59 per share payable on December 8, 2026.
⚠️ Management expects favorable group-life mortality ratios to normalize after a recent quarterly low of 79%.
🏢 MetLife holds a market cap of USD 63.4 billion and trades near its yearly high.
📅 Q3 2026 results are scheduled for release on November 4, 2026, followed by a conference call.
📊 The stock trades at EUR 87.89 as of October 9, 2026, slightly up from the prior close.
Bullish Signals
EPS rose 20% to USD 2.43 in Q2 2026.
Risk Factors
Mizuho lowered price target from $112 to $109.
Group-life mortality ratio normalized to 79%.
Bullish Signals
MetLife reported adjusted earnings per share of USD 2.43 for Q2 2026, a 20% year-over-year increase.
Adjusted earnings rose 15% to USD 1.6 billion with an adjusted return on equity reaching 17%.
The company declared a fourth-quarter dividend of USD 0.59 per share payable in December 2026.
MetLife achieved the top end of its annual target range for adjusted return on equity at 17%.
Risk Factors
Mizuho lowered its price target from USD 112 to USD 109, signaling analyst caution despite recent earnings beats.
Group-life mortality ratios normalized from a favorable quarterly low of 79%, which was below the 83%-88% annual target range.
MetLife Inc. (MET) shares rose 2.09% to EUR 87.61 in after-hours trading on October 8, 2026, with the NYSE quote at USD 98.17. The stock traded within its 52-week range of USD 67.33 to USD 100.93, sitting 2.76% below the yearly high. Trading volume was 40.11% of the average daily volume, indicating moderate activity ahead of the upcoming quarterly earnings release.
Analyst sentiment remains mixed regarding MetLife's valuation targets. Mizuho Securities lowered its price target from USD 112 to USD 109 while retaining an Outperform rating, whereas Barclays raised its target from USD 97 to USD 111 with an Overweight rating. Both analyst targets currently sit above the current market price, suggesting a range of expectations for future performance.
The company is preparing to release its third-quarter 2026 financial results on November 4, 2026, following the market close. A conference call is scheduled for November 5, 2026, between 9:00 a.m. and 10:00 a.m. ET. MetLife currently trades at a P/E ratio of 18.84 with a trailing dividend yield of 2.00 percent.
📈 MetLife stock rose 2.09% to EUR 87.61 in after-hours trading on Oct 8, 2026.
💰 Market cap is USD 63.2 billion with a P/E ratio of 18.84.
📅 Q3 2026 results are scheduled for release on Nov 4, 2026 after market close.
🎯 Mizuho lowered price target to USD 109 while maintaining an Outperform rating.
📈 Barclays raised price target to USD 111 and kept an Overweight rating.
📈 MetLife stock gained 2.09% to EUR 87.61 in after-hours trading on October 8, 2026.
💰 The company's market capitalization stands at USD 63.2 billion with a P/E ratio of 18.84.
📅 MetLife is scheduled to publish third-quarter 2026 results on November 4, 2026, after the market closes.
🎯 Mizuho lowered its price target from USD 112 to USD 109 while maintaining an Outperform rating.
📈 Barclays raised its price target from USD 97 to USD 111 and kept an Overweight rating.
📊 The stock traded at USD 98.17 on the NYSE, which is 2.50% above the previous close.
💸 MetLife offers a trailing dividend yield of 2.00 percent to shareholders.
Bullish Signals
Stock rose 2.09% in after-hours trading.
Barclays raised price target to USD 111.
Risk Factors
Mizuho cut price target from $112 to $109.
Bullish Signals
MetLife stock rose 2.09% in after-hours trading, closing at EUR 87.61 and USD 98.17 on the NYSE.
Barclays raised its price target from USD 97 to USD 111 while maintaining an Overweight rating.
Risk Factors
Mizuho lowered its price target from USD 112 to USD 109, though it retained an Outperform rating.
MetLife, Inc. announced on June 29, 2017, that its board of directors has approved the spin-off of Brighthouse Financial, a leading U.S. annuity and life insurance provider. The transaction is subject to the SEC declaring Brighthouse Financial's Registration Statement on Form 10 effective and obtaining necessary state insurance regulatory approvals.
Upon completion of the distribution, MetLife common shareholders will receive one share of Brighthouse Financial common stock for every 11 shares of MetLife common stock held as of the close of business on July 19, 2017. The record date is set for 5 p.m. New York City time on Wednesday, July 19, 2017, with the distribution scheduled to occur at 5 p.m. New York City time on Friday, August 4, 2017.
Following the spin-off, the price of MetLife common stock on the New York Stock Exchange will reflect the distribution of Brighthouse Financial shares, which may result in a lower share price prior to the distribution. Brighthouse Financial currently holds approximately 2.8 million insurance policies and annuity contracts in-force as an operating segment of MetLife.
MetLife, founded in 1868, operates globally with approximately 100 million customers across nearly 50 countries. The company serves as one of the largest life insurance companies in the world, providing life insurance, annuities, employee benefits, and asset management services.
🔄 Shareholders get one Brighthouse share for every 11 MetLife shares held.
💰 Distribution occurs August 4, 2017, at 5 p.m. New York City time.
📉 NYSE MetLife prices will adjust to reflect distributed Brighthouse value.
🏢 Brighthouse holds 2.8 million policies as the spun-off entity.
📅 MetLife's board approved the spin-off of Brighthouse Financial, subject to SEC effectiveness and state regulatory approvals.
🔄 Shareholders will receive one share of Brighthouse Financial for every 11 shares of MetLife held as of July 19, 2017.
💰 The distribution date is set for Friday, August 4, 2017, at 5 p.m. New York City time.
📉 Post-spin-off, MetLife share prices on the NYSE will adjust to reflect the value of the distributed Brighthouse shares.
🏢 Brighthouse Financial is a leading U.S. annuity and life insurance provider with approximately 2.8 million policies in-force.
🌍 MetLife operates globally with approximately 100 million customers across nearly 50 countries.
Bullish Signals
MetLife received state approvals for Brighthouse spin-off.
Strategic restructuring unlocks shareholder value via spin-off.
Risk Factors
Stock price may drop after Brighthouse Financial share distribution.
Spin-off depends on SEC approval of Brighthouse registration.
Bullish Signals
MetLife has secured necessary state insurance regulatory approvals for the spin-off of Brighthouse Financial, indicating a smooth path to completion.
The company is executing a strategic restructuring by spinning off its annuity and life insurance segment, potentially unlocking value for shareholders.
Risk Factors
Following the distribution of Brighthouse Financial shares, the price of MetLife common stock on the New York Stock Exchange will reflect the distribution and may be lower than before the spin-off.
The spin-off is contingent upon the SEC's timely declaration that Brighthouse Financial's Registration Statement on Form 10 is effective.
As of October 5, 2026, MetLife Inc. (MET) is trading at $94.43, with analysts from CleaRank Financial AI and Wall Street consensus maintaining a Buy rating and a median price target of $108.00, suggesting approximately 14.4% upside potential from current levels. The stock recently beat earnings per share estimates for the quarter ending June 2026 by 6.11%, accompanied by a positive stock price reaction of 3.83%, which signals underlying operational strength despite trading below its 50-day average.
MetLife offers shareholders a dividend yield of approximately 2.46%, providing a modest income stream, though insider activity shows a net selling pressure with $3.8 million in sales reported and no recent purchases, indicating a lack of strong insider conviction. Historical performance data indicates that a $10,000 investment in MET since October 2016 would be worth about $23,038 today, significantly underperforming the S&P 500 benchmark which reached approximately $35,693 over the same period.
CleaRank's Monte Carlo simulations project a base case price near $128 for MET by 2030, representing a 1.4x return from today's price assuming no dividends are reinvested, with a downside path ending near $59.36. These projections are based on statistical simulations of historical volatility and drift rather than specific price targets, highlighting the uncertainty inherent in long-term equity forecasting for the insurance sector.
📈 MetLife trades at $94.43 with $108.00 analyst target (14.4% upside).
📉 Insiders sold $3.8 million; no reported insider purchases.
💵 Offers 2.46% dividend yield to shareholders.
🔮 Monte Carlo projects $128 base case by 2030.
📈 MetLife trades at $94.43 with a consensus analyst price target of $108.00, indicating 14.4% upside potential.
💰 The company beat EPS estimates for the quarter ending June 2026 by 6.11%, driving a 3.83% positive stock price reaction.
📉 Insiders have sold $3.8 million worth of stock with no reported purchases, signaling caution among management.
💵 MetLife offers a dividend yield of approximately 2.46% to shareholders.
📊 A $10,000 investment in MET since October 2016 is valued at $23,038 today versus $35,693 for the S&P 500.
🔮 Monte Carlo simulations project a base case price of $128 for MET by 2030 with a downside path near $59.36.
Bullish Signals
EPS beat estimates by 6.11% in Q2 2026.
Stock rose 3.83% on strong operational results.
Offers a dividend yield of approximately 2.46%.
Risk Factors
Insiders sold $3.8M stock with no purchases.
Underperformed S&P 500; $10k invested grew to $23,038 vs $35,693.
Bullish Signals
MetLife beat EPS estimates for the quarter ending June 2026 by 6.11%, signaling operational strength and driving a positive stock price reaction of 3.83%.
The company offers a dividend yield of approximately 2.46%, providing a modest income stream to shareholders.
Risk Factors
Insiders have sold $3.8 million worth of stock with no reported purchases, indicating a lack of strong insider conviction and potentially signaling caution.
Historical performance shows significant underperformance relative to the S&P 500 benchmark, with a $10,000 investment in MET since October 2016 valued at $23,038 compared to $35,693 for the index.
MetLife Inc. received a USD 115 price target from Jefferies on October 1, 2026, maintaining its Buy rating for the stock. This new target represents a 21.8 percent premium over MetLife's trading price of USD 94.43 as of October 2, 2026. The analyst decision follows Piper Sandler's recent upgrade in late September, which raised its target from USD 99.00 to USD 110.00, contributing to a current consensus Buy rating among 12 analysts with an average price target of USD 104.31.
MetLife reported strong second-quarter results that support the bullish analyst sentiment. Adjusted earnings per share rose 20 percent year-over-year to USD 2.43, while adjusted net income increased 15 percent to USD 1.6 billion. The company achieved an adjusted return on equity of 17.0 percent, hitting the top end of its annual target range between 15 percent and 17 percent. Revenue driven by premiums, fees, and other sources grew 7 percent to USD 13.7 billion for the quarter.
Looking ahead to the third quarter ended September 30, 2026, MetLife estimates pre-tax variable investment income of at least USD 600 million, covering private equity, real estate, and other funds along with prepayment fees. The company is scheduled to release its final Q3 earnings report and financial supplement on November 4, 2026, which will provide a definitive update on these preliminary estimates. As of October 2, 2026, MetLife's stock traded at USD 94.43, sitting 6.44 percent below its 52-week high of USD 100.93 with a market capitalization of USD 60.8 billion.
📈 Jefferies maintains Buy rating with new $115 price target for MetLife.
💰 Q2 adjusted EPS rose 20% year-over-year to $2.43 driven by operations.
📊 Adjusted return on equity hit 17%, reaching top of annual target range.
💵 Premiums and fees grew 7% to $13.7 billion in the quarter ended Sept 30, 2026.
📅 MetLife scheduled to release Q3 earnings report on November 4, 2026.
📈 Jefferies maintained a Buy rating on MetLife and set a new price target of USD 115.00, which is 21.8 percent above the current stock price.
💰 Q2 adjusted earnings per share rose 20 percent year-over-year to USD 2.43, driven by strong operational performance.
📊 Adjusted return on equity reached 17.0 percent in the second quarter, hitting the top end of MetLife's annual target range of 15 percent to 17 percent.
💵 Premiums, fees, and other revenues grew 7 percent to USD 13.7 billion during the quarter ended September 30, 2026.
📈 The company estimated at least USD 600 million in pre-tax variable investment income for the third quarter, covering private equity and real estate funds.
🤝 Analyst consensus remains bullish with a Buy rating from 12 analysts and an average price target of USD 104.31.
📉 MetLife stock traded at USD 94.43 on October 2, 2026, sitting 6.44 percent below its 52-week high of USD 100.93.
🏦 The company's market capitalization stood at USD 60.8 billion as of the latest trading session.
📅 MetLife is scheduled to release its third-quarter earnings report and financial supplement on November 4, 2026.
🔄 Piper Sandler previously raised its price target from USD 99.00 to USD 110.00 in late September, contributing to the positive analyst sentiment.
Bullish Signals
Q2 EPS rose 20% to USD 2.43.
Adjusted ROE hit 17%, meeting annual target.
Revenue grew 7% YoY to USD 13.7B.
Analysts bullish with avg price target USD 104.31.
Bullish Signals
MetLife adjusted Q2 EPS rose 20 percent to USD 2.43, demonstrating strong earnings growth.
Adjusted return on equity reached 17.0 percent, hitting the top of MetLife's annual target range of 15 percent to 17 percent.
Premiums, fees, and other revenues grew 7 percent year-over-year to USD 13.7 billion in Q2 2026.
Analyst consensus remains bullish with a Buy rating from 12 analysts and an average price target of USD 104.31, which is 10.46 percent above the current stock price.
Jefferies maintained its Buy rating and set a USD 115.00 price target on October 1, 2026, signaling continued confidence in the company's performance.
Piper Sandler raised its price target from USD 99.00 to USD 110.00 on September 22, 2026, further supporting the positive analyst sentiment.
Jefferies analyst Suneet Kamath maintained a Buy rating for MetLife Inc. (MET) with a price target of USD 115.00, providing a fresh valuation reference while leaving the recommendation unchanged. The stock was trading around EUR 84.16 on October 2, 2026, which translates to approximately USD 94.67, placing it below its yearly high of USD 100.93.
MetLife reported strong second-quarter results for the period ended June 30, 2026, with revenue reaching USD 18.88 billion and net profit at USD 736 million, representing year-over-year growth. Adjusted earnings rose 15% to USD 1.6 billion, while adjusted earnings per share increased 20% to USD 2.43, driven by a 7% increase in premiums, fees, and other revenues.
The company provided preliminary guidance for the third quarter, estimating at least USD 600 million in pre-tax variable investment income. This estimate is unaudited as the quarter-end closing process was incomplete, with investors expected to test this figure against reported results when MetLife releases its Q3 earnings and financial supplement on November 4, 2026.
📈 Jefferies maintains Buy rating on MET with $115 price target.
💰 MET Q2 revenue grew to $18.88B with $736M net profit.
📊 Adjusted EPS rose 20% to $2.43 in Q2 2026.
🚀 Premiums and fees increased 7% to $13.7 billion.
📅 MET expects at least $600M pre-tax variable income for Q3.
📈 Jefferies analyst Suneet Kamath maintains a Buy rating for MetLife with a USD 115.00 price target.
💰 MetLife reported Q2 revenue of USD 18.88 billion and net profit of USD 736 million, both showing growth compared to the prior year.
📊 Adjusted earnings per share increased 20% to USD 2.43 in the second quarter of 2026.
🚀 Premiums, fees, and other revenues grew 7% to USD 13.7 billion during the reported period.
📅 MetLife estimates at least USD 600 million in pre-tax variable investment income for Q3 2026.
📉 The stock trades below its yearly high of USD 100.93 with a market cap of USD 60.9 billion.
Bullish Signals
Jefferies maintains Buy rating on MetLife.
Revenue grew to USD 18.88 billion.
Net profit reached USD 736 million.
Adjusted EPS surged 20% year-over-year.
Premiums expanded by 7% to USD 13.7 billion.
Risk Factors
Stock trades below yearly high of USD 100.93 at USD 94.67.
Q3 investment income estimate is preliminary and unaudited.
Bullish Signals
Jefferies analyst Suneet Kamath maintains a Buy rating for MetLife, signaling continued confidence in the company's financial trajectory.
MetLife reported robust Q2 results with revenue growing to USD 18.88 billion and net profit reaching USD 736 million.
Adjusted earnings per share surged 20% year-over-year to USD 2.43, demonstrating strong operational performance.
Premiums, fees, and other revenues expanded by 7% to USD 13.7 billion, indicating healthy top-line growth.
The company provided a preliminary Q3 estimate of at least USD 600 million in pre-tax variable investment income.
Risk Factors
MetLife's stock price remains below its yearly high of USD 100.93, trading at approximately USD 94.67 as of October 2, 2026.
The Q3 investment income estimate is preliminary and unaudited, with actual results potentially differing materially due to incomplete quarter-end closing processes.
Wall Street Zen has upgraded MetLife Inc. stock from Hold to Buy, signaling a positive shift in analyst sentiment regarding the insurer's prospects. This upgrade follows recent financial disclosures where MetLife estimated at least USD 600 million in pre-tax variable investment income for the third quarter of 2026.
MetLife reported second-quarter 2026 results showing total revenue of USD 19.2 billion and consolidated net income of USD 779.0 million. However, diluted earnings per share declined sequentially to USD 1.09 from USD 1.74 in the first quarter, representing a significant drop in profitability.
The company is scheduled to release its official quarterly earnings report and financial supplement on November 4, 2026. Investors will be closely watching this filing to determine if the preliminary third-quarter investment income figure aligns with expectations and how it impacts the full-year guidance of USD 1.6 billion.
📈 Wall Street Zen upgraded MetLife stock from Hold to Buy.
💰 MetLife estimated USD 600M pre-tax variable investment income for Q3 2026.
📉 Diluted EPS fell sequentially to USD 1.09 in Q2 2026.
🏦 MetLife reported USD 19.2B revenue and USD 779M net income in Q2 2026.
📅 Company plans to release official quarterly earnings report on November 4, 2026.
📈 Wall Street Zen upgraded MetLife stock from Hold to Buy, indicating improved analyst confidence in the company's outlook.
💰 MetLife estimated at least USD 600 million in pre-tax variable investment income for the third quarter of 2026.
📉 Diluted earnings per share fell sequentially to USD 1.09 in Q2 2026, down from USD 1.74 in Q1 2026.
🏦 MetLife reported total revenue of USD 19.2 billion and net income of USD 779.0 million for the second quarter of 2026.
📅 The company plans to release its official quarterly earnings report on November 4, 2026.
📊 MetLife stock traded at EUR 82.83 on October 1, 2026, reflecting a slight decline of 0.34% versus the prior close.
🎯 The third-quarter investment income estimate represents approximately 37.5% of the full-year 2026 variable investment income guidance.
Bullish Signals
Wall Street Zen upgraded stock from Hold to Buy.
Estimated $600M pre-tax variable investment income for Q3 2026.
Risk Factors
EPS dropped to USD 1.09 in Q2 2026 from USD 1.74 in Q1 2026.
Q3 income estimate covers only variable income, not total earnings.
Bullish Signals
Wall Street Zen upgraded MetLife stock from Hold to Buy, reflecting a positive change in analyst sentiment regarding the insurer's future performance.
MetLife estimated at least USD 600 million in pre-tax variable investment income for the third quarter of 2026, demonstrating strong investment returns.
Risk Factors
Diluted earnings per share declined sequentially to USD 1.09 in Q2 2026 from USD 1.74 in Q1 2026, indicating a significant drop in quarterly profitability.
The third-quarter investment income estimate covers only variable investment income rather than total earnings, which may not fully reflect the company's overall operational performance.
MetLife Inc. (MET) saw its stock trade at EUR 84.12 on September 29, 2026, reflecting a negligible decline of 0.08% against the prior close. The company recently reported strong second-quarter performance with adjusted earnings per share rising 20% to USD 2.43 and total assets reaching USD 759.4 billion as of June 30, 2026.
Investors are closely watching a preliminary estimate for Q3 variable investment income, which the company expects to be at least USD 600 million on a pre-tax basis. This metric is critical for MetLife given its heavy reliance on investment portfolio performance to drive overall earnings, with commercial mortgage loans accounting for 17% of its investments as of mid-2026.
Analyst sentiment remains constructive despite the flat daily trading action. Fitch Ratings affirmed MetLife's credit ratings with a stable outlook citing strong diversification, while Wall Street Zen upgraded the stock from hold to buy, setting an average price target of USD 104.31 against a current market cap of USD 61.7 billion.
📉 MetLife stock traded at EUR 84.12, down 0.08% on Sept 29, 2026.
📈 Q2 adjusted EPS surged 20% to USD 2.43 with USD 1.6B earnings.
💰 Company holds USD 759.4B assets and generated USD 2.2B operating cash flow.
🔮 MetLife estimates at least USD 600M pre-tax variable investment income for Q3.
🚀 Wall Street Zen upgraded MetLife to buy with a USD 104.31 price target.
📉 MetLife stock traded at EUR 84.12 on September 29, 2026, down 0.08% versus the previous close.
📈 Q2 adjusted EPS surged 20% to USD 2.43, driven by a 15% increase in adjusted earnings to USD 1.6 billion.
💰 The company holds USD 759.4 billion in total assets and generated USD 2.2 billion in operating cash flow during Q2 2026.
🔮 MetLife estimates at least USD 600 million in pre-tax variable investment income for the quarter ending September 30, 2026.
🏦 Commercial mortgage loans represent 17% of MetLife's investment portfolio as of the first half of 2026.
⭐ Fitch Ratings affirmed MetLife's credit ratings with a stable outlook, highlighting strong diversification across its business lines.
🚀 Wall Street Zen upgraded MetLife from hold to buy, establishing an average analyst price target of USD 104.31.
📊 The stock trades within a 52-week range of USD 67.33 to USD 100.93 with a market capitalization of USD 61.7 billion.
Bullish Signals
Q2 adjusted EPS rose 20% to USD 2.43.
Operating cash flow reached USD 2.2 billion in Q2 2026.
Fitch affirmed credit ratings with a stable outlook.
Wall Street Zen upgraded stock to buy.
Risk Factors
Commercial mortgages are 17% of portfolio, raising sector risks per Fitch.
GAAP net income fell to $705M in Q2 from $1.14B in Q1.
Bullish Signals
MetLife reported a significant 20% increase in Q2 adjusted EPS, reaching USD 2.43, demonstrating strong operational profitability.
The company generated substantial operating cash flow of USD 2.2 billion in the second quarter of 2026.
Fitch Ratings affirmed MetLife's credit ratings with a stable outlook, validating its strong diversification strategy.
Wall Street Zen upgraded MetLife from hold to buy, reflecting positive analyst sentiment and a target price above current levels.
Risk Factors
Commercial mortgage loans constitute 17% of the investment portfolio, exposing the company to potential sector-specific risks identified by Fitch.
GAAP net income dropped to USD 705 million in Q2 compared to USD 1.14 billion in Q1, highlighting volatility driven by investment results.
AMMB Holdings Bhd and MetLife International Holdings LLC are reportedly weighing strategic options for their joint-venture insurance businesses, AmMetLife Insurance Bhd and AmMetLife Takaful Bhd. Sources indicate the parties are considering all possibilities, including a potential sale of the venture, amidst a flurry of mergers and acquisitions in Malaysia's insurance sector.
The review follows a failed 2023 attempt to sell the joint venture to Great Eastern Holdings for RM1.12 billion due to regulatory hurdles. Since that termination, AMMB and MetLife have shifted focus back to building the business, appointing new leadership and consolidating their conventional insurance operations onto a shared platform while maintaining separate takaful entities for regulatory compliance.
Financially, AmMetLife Insurance reported a 5.9% year-on-year profit increase to RM37.8 million in FY2026, though gross written premiums declined by 3.6%. Conversely, the takaful arm narrowed its loss to RM6.3 million driven by strong top-line growth of 51.8% in gross written premiums. AMMB's total insurance segment profit rose slightly to RM105 million, representing 5% of the group's total FY2026 profit.
The joint venture faces headwinds including rising medical inflation and intensifying competition. In the first quarter of FY2027, AMMB's insurance profit fell significantly to RM8.6 million from RM32.4 million a year earlier, primarily due to lower investment income and net earned premiums. Despite these challenges, the recent operational restructuring suggests shareholders still see value in the business.
📉 AmMetLife FY2026 profit rose 5.9% to RM37.8m despite premium drop.
⚠️ Q1FY2027 insurance profit fell sharply due to lower investment income.
📉 Takaful loss narrowed to RM6.3m as premiums surged 51.8%.
⚠️ Business faces medical inflation, cost pressures, and intensifying competition.
📰 AMMB and MetLife are weighing strategic options for their insurance joint venture, including a possible sale.
🔄 The review is prompted by recent M&A activity in Malaysia's insurance sector following a failed 2023 exit attempt to Great Eastern.
👔 AMMB appointed Wan Saifulrizal Wan Ismail as CEO of AmMetLife Insurance in March, succeeding Rangam Bir.
💻 The group consolidated conventional insurance and takaful operations onto one shared platform while closing the agency channel.
📈 AmMetLife Insurance profit after tax rose 5.9% to RM37.8 million in FY2026 despite a 3.6% drop in gross written premiums.
📉 AmMetLife Takaful narrowed its loss to RM6.3 million in FY2026 as gross written premiums surged 51.8% to RM288.9 million.
📊 AMMB's total insurance segment profit increased slightly to RM105 million, accounting for 5% of the group's total FY2026 profit.
⚠️ In 1QFY2027, AMMB's insurance profit fell sharply to RM8.6 million due to lower investment income and net earned premiums.
🏥 The business faces challenges including rising medical inflation, cost pressures, and intensifying competition in the market.
Bullish Signals
MetLife maintains ~50% stake in AmMetLife ventures.
Risk Factors
Joint venture sale options being weighed with AMMB.
Previous sale deal failed due to regulatory issues.
Gross written premiums declined 3.6% in FY2026.
Q1FY2027 profit fell significantly to RM8.6 million.
Decline driven by lower investment income and premiums.
Bullish Signals
MetLife is maintaining a roughly 50% stake in AmMetLife Insurance Bhd and AmMetLife Takaful Bhd alongside AMMB.
The joint venture narrowed its loss to RM6.3 million in FY2026, driven by strong top-line growth with gross written premiums rising 51.8% to RM288.9 million.
AmMetLife Insurance reported a profit after tax increase of 5.9% year-on-year to RM37.8 million in FY2026.
Risk Factors
AMMB and MetLife are reportedly weighing options including a possible sale of their insurance joint venture business.
A previous deal to sell the venture to Great Eastern for RM1.12 billion failed due to regulatory issues in Malaysia and Singapore.
AmMetLife Insurance gross written premiums declined 3.6% year-on-year to RM774.8 million in FY2026.
In 1QFY2027, AMMB's insurance profit after tax fell significantly to RM8.6 million from RM32.4 million a year earlier.
The decline in Q1FY2027 profit was mainly due to lower investment income and net earned insurance premiums.
MetLife Inc. stock traded at USD 97.25 on the NYSE on September 24, 2026, approaching its 52-week high of USD 100.93 with a market capitalization of USD 62.57 billion. The insurer provided preliminary estimates for Q3 variable investment income of at least USD 600 million pre-tax, which serves as an early operating signal ahead of its scheduled results release on November 4, 2026.
In the second quarter of 2026, MetLife reported diluted GAAP EPS of USD 1.09 and consolidated net income of USD 779 million. On an adjusted basis, earnings reached USD 2.43 per share, representing a 20 percent year-over-year increase. The company achieved an adjusted Return on Equity (ROE) of 17 percent, hitting the top end of its annual target range between 15 percent and 17 percent.
Analyst sentiment remains positive with Piper Sandler upgrading MetLife to Overweight and setting a price target of USD 110.00, which implies significant upside from current levels. Additionally, Group Benefits adjusted earnings surged 25 percent year over year to USD 503 million, driven by a mortality ratio of 79 percent that outperformed the company's internal target range.
The article highlights MetLife's strong financial performance across investment income and underwriting metrics, supported by institutional upgrades. While the Q3 estimate is preliminary and unaudited, it suggests robust contribution toward the full-year guidance of USD 1.6 billion in pre-tax variable investment income.
📈 MetLife stock nears $100.93 high with $62.57B market cap.
💰 Q3 variable income projected at least $600M pre-tax.
📊 Q2 adjusted EPS rose 20% to $2.43.
🎯 Adjusted ROE hit top of target range at 17%.
🚀 Piper Sandler upgrades MetLife to Overweight with $110 target.
📈 MetLife stock traded at USD 97.25 on September 24, 2026, trading near its 52-week high of USD 100.93 with a market cap of USD 62.57 billion.
💰 The insurer estimated Q3 variable investment income at least USD 600 million pre-tax, contributing to full-year guidance of USD 1.6 billion.
📊 Q2 adjusted EPS rose 20 percent year over year to USD 2.43, with diluted GAAP EPS reaching USD 1.09.
🎯 Adjusted ROE hit 17 percent, achieving the top of the company's annual target range of 15 percent to 17 percent.
🚀 Piper Sandler upgraded MetLife to Overweight with a price target of USD 110.00, indicating analyst confidence in valuation upside.
🏆 Group Benefits adjusted earnings increased 25 percent year over year to USD 503 million in Q2 2026.
✅ The Group Life mortality ratio improved to 79 percent, beating the company's target range of 83 percent to 88 percent.
Bullish Signals
Stock trades near 52-week high of USD 100.93.
Q2 EPS surged 20% YoY to USD 2.43.
Adjusted ROE hit 17%, meeting annual target.
Group Benefits earnings jumped 25% YoY.
Piper Sandler upgraded to Overweight with USD 110 target.
Bullish Signals
MetLife stock is trading near its 52-week high of USD 100.93 at USD 97.25, indicating strong market confidence and momentum.
Q2 adjusted earnings per share surged 20 percent year over year to USD 2.43, demonstrating robust profitability growth.
The company achieved an adjusted ROE of 17 percent, successfully hitting the top end of its annual target range.
Group Benefits adjusted earnings jumped 25 percent year over year to USD 503 million, showing strong segment performance.
The Group Life mortality ratio improved to 79 percent, significantly outperforming the company's internal target range.
Piper Sandler upgraded MetLife to Overweight with a price target of USD 110.00, suggesting substantial upside potential from current levels.
Preliminary Q3 variable investment income is estimated at least USD 600 million pre-tax, supporting strong full-year guidance.
MetLife Inc. (NYSE: MET) shares gained 0.99 percent to close at USD 21.35 on September 23, 2026, trading above the prior session's close of USD 21.14. The stock opened at USD 21.07 and finished USD 0.21 higher, with a daily trading volume of 81,830 shares that significantly exceeded the average volume of 44,648 shares.
Despite the broader S&P 500 declining 0.8 percent to 7,706.03 on the same date, MetLife's performance outperformed the index by 1.79 percentage points. The stock traded within a session range of USD 20.94 to USD 21.47, remaining below its 52-week high of USD 24.29 but above the 52-week low of USD 20.38.
Analyst sentiment improved for the insurer following an upgrade from Neutral to Overweight by Piper Sandler on September 22, 2026. Market attention is also focused on upcoming U.S. economic data scheduled for release on September 24, including second-quarter current account figures and August new-home sales, which could influence rate-sensitive financial stocks like MetLife.
MetLife's preferred security also saw gains of 0.99 percent on the NYSE during this session. The company's ISIN is US59156R1086, and its stock price action reflects a resilient performance against a backdrop of mixed macroeconomic indicators.
📈 MetLife stock gained 0.99% to close at USD 21.35.
📊 Trading volume hit 81,830 shares, nearly double the average.
🏆 Stock outperformed S&P 500 by 1.79 percentage points.
🔼 Piper Sandler upgraded MetLife from Neutral to Overweight.
📅 Upcoming economic data may impact rate-sensitive MetLife stocks.
📈 MetLife stock closed at USD 21.35 on September 23, 2026, gaining 0.99 percent to finish above its prior close.
📊 Trading volume reached 81,830 shares, nearly double the average daily volume of 44,648 shares.
🏆 The stock outperformed the S&P 500, which fell 0.8 percent, by a margin of 1.79 percentage points.
📉 MetLife's share price remains USD 2.94 below its 52-week high of USD 24.29 and USD 0.97 above the 52-week low.
🔼 Piper Sandler upgraded MetLife from Neutral to Overweight on September 22, 2026, boosting analyst sentiment.
📅 Upcoming U.S. economic data releases on September 24 could impact rate-sensitive financial stocks including MetLife.
Bullish Signals
Stock gained 0.99% to close at USD 21.35.
Trading volume of 81,830 shares exceeded average daily volume.
Piper Sandler upgraded MetLife from Neutral to Overweight.
Bullish Signals
MetLife stock gained 0.99 percent to close at USD 21.35, outperforming the broader S&P 500 which fell 0.8 percent on the same day.
Trading volume of 81,830 shares significantly exceeded the average daily volume of 44,648 shares, indicating strong investor interest ahead of the open.
Piper Sandler upgraded MetLife from Neutral to Overweight on September 22, 2026, signaling improved analyst confidence in the company's prospects.
MetLife Inc. (MET) closed its shares at USD 95.92 on the NYSE on September 22, 2026, marking a slight decline of 0.75 percent from the prior session. The stock price hovered near the USD 96 level as investors digested mixed signals from the company's second-quarter financial results and recent analyst sentiment.
Financially, MetLife reported adjusted earnings per share (EPS) of USD 2.43 for the second quarter of 2026, which exceeded the consensus FactSet estimate of USD 2.30. However, total revenue came in at USD 13.65 billion, falling significantly short of the FactSet forecast of USD 19.67 billion, creating a divergence between profitability and top-line growth expectations.
Analyst sentiment has shifted positively following an upgrade to a Buy rating by Kabutan on September 22, 2026. The broader analyst consensus currently projects an average price target of USD 105.75, representing a potential upside of approximately 10.25 percent from the closing price, with individual targets ranging between USD 84.00 and USD 119.00.
The market is currently weighing the strength of MetLife's adjusted earnings beat against its underwhelming revenue performance. While the stock remains close to the USD 96 mark, the upgraded rating suggests that analysts view the company's profitability metrics as a more reliable indicator of value than the reported revenue shortfall at this time.
📉 MetLife stock closed down 0.75% at USD 95.92 on Sept 22, 2026.
💰 Q2 adjusted EPS of USD 2.43 beat analyst estimates.
📉 Q2 revenue of USD 13.65 billion missed the USD 19.67 billion estimate.
🔼 Kabutan upgraded MetLife to Buy rating on Sept 22, 2026.
🎯 Average price target is USD 105.75, implying 10.25% upside.
📉 MetLife Inc. closed at USD 95.92 on September 22, 2026, down 0.75 percent from the previous trading session.
💰 The company reported second-quarter adjusted EPS of USD 2.43, beating the FactSet estimate of USD 2.30.
📉 Reported revenue for Q2 2026 was USD 13.65 billion, missing the FactSet estimate of USD 19.67 billion.
🔼 Kabutan upgraded MetLife to a Buy rating on September 22, 2026, supporting recent bullish analyst sentiment.
🎯 The average analyst price target stands at USD 105.75, implying roughly 10.25 percent upside from the current close.
📊 Trading volume reached 253 million dollars on September 22, 2026, as investors assessed the mixed earnings report.
Bullish Signals
Kabutan upgraded MetLife to Buy on Sept 22, 2026.
Risk Factors
Revenue missed estimates by $6B in Q2.
Stock fell 0.75% due to revenue miss.
Bullish Signals
MetLife received a Buy rating upgrade from Kabutan on September 22, 2026, signaling renewed analyst confidence in the company's strategic direction.
The company beat adjusted EPS expectations with second-quarter results of USD 2.43 versus the consensus estimate of USD 2.30.
Analysts maintain an average price target of USD 105.75, suggesting a potential upside of 10.25 percent from the current trading price.
The stock is supported by strong profitability metrics that outperformed forecasts despite a revenue shortfall.
Risk Factors
MetLife reported second-quarter revenue of USD 13.65 billion, which was significantly below the FactSet estimate of USD 19.67 billion.
The stock declined 0.75 percent to close at USD 95.92 on September 22, 2026, reflecting market caution regarding the revenue miss.
MetLife Inc. stock traded at USD 97.08 on September 18, 2026, positioning the life insurer near its 52-week high of USD 100.93 with a market capitalization of USD 62.47 billion. The company recently reported strong financial performance for the second quarter of 2026, beating analyst expectations and demonstrating robust operational metrics that support its current valuation.
For the second quarter of 2026, MetLife earned USD 2.43 per share, surpassing the consensus estimate of USD 2.30 by USD 0.13. Revenue increased 10.5 percent year over year to reach USD 13.52 billion, while net margins improved to 4.57 percent and return on equity climbed to 23.39 percent, highlighting a healthy operating profile.
Analyst sentiment remains largely positive despite the stock trading close to its yearly peak. The consensus rating is Moderate Buy with an average 12-month price target of USD 102.77. While Wall Street Zen recently cut its rating to Hold, major institutions like Morgan Stanley and Wells Fargo have raised their price targets to USD 111.00 and USD 109.00 respectively.
MetLife is scheduled to report earnings again on November 9, 2026. Until then, investors are focusing on the gap between the current stock price and the analyst consensus target, as well as the proximity to the 52-week high, which serves as a key reference point for near-term trading activity.
📈 MetLife traded at $97.08, just below its $100.93 52-week high.
💰 Q2 EPS beat estimates at $2.43 with revenue up 10.5%.
🏆 Net margin improved to 4.57% and ROE reached 23.39%.
🎯 Average analyst target is $102.77, indicating upside potential.
📅 Next earnings report scheduled for November 9, 2026.
📈 MetLife stock traded at USD 97.08 on September 18, 2026, placing it just below its 52-week high of USD 100.93.
💰 Q2 2026 EPS reached USD 2.43, beating the consensus estimate of USD 2.30 by USD 0.13.
📊 Revenue grew 10.5 percent year over year to USD 13.52 billion in the second quarter of 2026.
🏆 Net margin improved to 4.57 percent with return on equity reaching 23.39 percent for the quarter.
🎯 The average 12-month analyst price target is USD 102.77, suggesting upside potential from current levels.
📉 Wall Street Zen cut MetLife to Hold, though the broader consensus remains Moderate Buy with 11 buy ratings.
🚀 Morgan Stanley raised its price target from USD 103.00 to USD 111.00 following recent performance.
🏦 Wells Fargo lifted its price target from USD 101.00 to USD 109.00, reinforcing bullish sentiment.
📅 The next earnings report is scheduled for November 9, 2026, providing a key catalyst for traders.
📉 Daily volume was 7.31 million shares with the stock trading in a 50-day range of USD 92.24 to USD 100.06.
Bullish Signals
Q2 EPS beat estimates at USD 2.43.
Revenue rose 10.5% YoY to USD 13.52B.
Net margin expanded to 4.57% and ROE hit 23.39%.
Stock trades near 52-week high on strong fundamentals.
Risk Factors
Wall Street Zen downgraded MetLife to Hold.
Stock trades $3.85 below 52-week high.
Bullish Signals
MetLife reported Q2 2026 EPS of USD 2.43, beating the consensus estimate of USD 2.30 by USD 0.13.
Revenue rose 10.5 percent year over year to USD 13.52 billion in the second quarter of 2026.
Net margin expanded to 4.57 percent while return on equity reached 23.39 percent for the quarter.
The stock is trading near its 52-week high, indicating strong investor confidence in the company's fundamentals.
Morgan Stanley raised its price target from USD 103.00 to USD 111.00, signaling increased bullishness.
Wells Fargo lifted its price target from USD 101.00 to USD 109.00, supporting the Moderate Buy consensus.
The average 12-month analyst price target of USD 102.77 suggests potential upside from the current trading price.
Risk Factors
Wall Street Zen cut MetLife's rating to Hold, introducing a dissenting voice in the analyst consensus.
The stock is trading approximately USD 3.85 below its 52-week high, limiting immediate momentum near resistance levels.
MetLife Inc. (NYSE: MET) shares opened flat, gaining 0.1% to close at USD 97.35 on September 17, 2026, trading within its upper half of the 52-week range between USD 67.33 and USD 100.93. The stock outperformed broader benchmarks significantly over the year-to-date period, delivering a 25.93% gain compared to the S&P 500's 11.57%, while also posting a strong one-year return of 27.26% versus the index's 15.72%. Trading volume reached approximately 2.76 million shares, reflecting steady investor interest in the life insurer.
Market sentiment remains anchored by the company's recent Q2 2026 financial performance, which saw earnings beat consensus expectations of USD 2.30 per share with actual results of USD 2.43 per share. Quarterly revenue was reported at around USD 19.07 billion, reinforcing positive investor confidence ahead of the next scheduled earnings release on November 9, 2026. The stock's valuation is further supported by a regular annual dividend of approximately USD 2.37 per share and a newly authorized USD 3.0 billion share buyback program for 2026.
Broader macroeconomic factors continue to influence MetLife's trading environment, with recent declines in bond yields and oil prices providing a supportive backdrop for financial stocks. While the S&P 500 advanced 1.14% and the Nasdaq Composite climbed 1.69% on September 17, MetLife lagged these broader equity benchmarks despite its modest uptick. Investors are currently positioning ahead of the upcoming November earnings update, monitoring how interest rate expectations and equity market risk appetite will impact the insurer's future performance.
📈 MetLife stock closed at USD 97.35, edging up 0.1% on September 17, 2026.
🚀 Company delivered 25.93% year-to-date gain versus S&P 500's 11.57%.
💰 Q2 2026 earnings of USD 2.43 per share beat consensus expectations.
💸 Board authorized USD 3.0 billion share buyback program for 2026.
🏦 MetLife pays regular annual dividend of around USD 2.37 per share.
📈 MetLife stock closed at USD 97.35 on September 17, 2026, edging up 0.1% with a day range between USD 96.80 and USD 98.32.
🚀 The company delivered a 25.93% year-to-date gain versus the S&P 500's 11.57%, highlighting strong relative outperformance over the current fiscal year.
💰 MetLife reported Q2 2026 earnings of USD 2.43 per share, beating consensus expectations of USD 2.30 per share.
📊 Quarterly revenue for the second quarter of 2026 was reported at approximately USD 19.07 billion.
💸 The company's board has authorized a USD 3.0 billion share buyback program for 2026 to support shareholder value.
🏦 MetLife pays a regular annual dividend of around USD 2.37 per share, providing consistent income to investors.
📅 The next scheduled earnings date is set for November 9, 2026, as per the Nasdaq-based earnings calendar.
📉 Despite its modest gain, MetLife lagged the S&P 500's 1.14% advance and the Nasdaq Composite's 1.69% climb on September 17.
🌍 Recent declines in bond yields and oil prices have created a supportive macroeconomic backdrop for financial stocks like MetLife.
Bullish Signals
EPS beat consensus at USD 2.43 vs USD 2.30.
Bullish Signals
MetLife reported Q2 2026 earnings of USD 2.43 per share, beating consensus expectations of USD 2.30 per share.
The company delivered a 25.93% year-to-date gain versus the S&P 500's 11.57%, demonstrating strong relative outperformance.
MetLife has authorized a USD 3.0 billion share buyback program for 2026 to support shareholder value.
The company reported quarterly revenue of around USD 19.07 billion in Q2 2026, confirming solid top-line growth.
MetLife offers a regular annual dividend of approximately USD 2.37 per share, providing consistent income to investors.
MetLife Inc. (MET) stock traded near its recent closing levels on September 11, 2026, as investors digested the company's latest quarterly financial results and dividend information. The insurer reported a quarterly earnings per share of USD 2.43, which beat the consensus estimate of USD 2.30 by USD 0.13. This performance highlighted a period of double-digit revenue growth and improved profitability for the global insurance and financial services group.
Financial metrics provided by MarketBeat indicate that MetLife's quarterly revenue reached USD 13.52 billion, representing a 10.5 percent increase from the same quarter a year prior. The company also reported a return on equity of 23.39 percent and a net margin of 4.57 percent for the latest quarter, demonstrating strong capital efficiency despite modest margins typical for large insurers.
MetLife continues to support its investment case with a quarterly dividend of USD 0.5925 per share, yielding approximately 2.4 percent annually based on current expectations. Analysts expect full-year earnings per share of USD 9.78, suggesting the company can maintain conservative payout ratios while distributing income. The stock closed within its established 52-week range, tracking broadly with the S&P 500 index as it consolidates following the earnings release.
Overall, the combination of rising earnings per share, solid return on equity, and a covered dividend forms the central narrative for MetLife's current valuation. Investors are weighing these positive fundamentals against the stock's consolidation phase while awaiting future catalysts such as updated guidance or capital management actions.
📈 EPS beat consensus by $0.13 at $2.43.
💰 Revenue rose 10.5% to $13.52 billion.
📊 ROE reached 23.39% with a 4.57% net margin.
💵 Quarterly dividend of $0.5925 offers 2.4% yield.
🔭 Full-year EPS guidance set at $9.78.
📈 MetLife reported quarterly earnings per share of USD 2.43, beating the consensus estimate of USD 2.30 by USD 0.13.
💰 Quarterly revenue reached USD 13.52 billion, marking a 10.5 percent increase from the same quarter a year earlier.
📊 The company achieved a return on equity of 23.39 percent and a net margin of 4.57 percent for the latest quarter.
💵 MetLife paid a quarterly dividend of USD 0.5925 per share, equivalent to an annualized yield of about 2.4 percent.
📉 The stock closed within its established 52-week range on September 11, 2026, tracking broadly with the S&P 500 index.
🔭 Analysts expect MetLife to deliver full-year earnings per share of USD 9.78 for the current fiscal year.
Bullish Signals
EPS beat estimates by $0.13 at $2.43.
ROE reached 23.39% with a 4.57% net margin.
Revenue rose 10.5% year-over-year to $13.52B.
Quarterly dividend yield stands at 2.4%.
Bullish Signals
MetLife reported quarterly earnings per share of USD 2.43, beating the consensus estimate of USD 2.30 by USD 0.13.
The company achieved a return on equity of 23.39 percent and a net margin of 4.57 percent for the latest quarter.
MetLife reported quarterly revenue of USD 13.52 billion, marking a 10.5 percent increase from the same quarter a year earlier.
The company pays a quarterly dividend of USD 0.5925 per share with an annualized yield of about 2.4 percent.
MetLife Inc. (MET) operates as one of the world's largest life insurance and employee benefits companies, with significant operations in the United States and a broad international presence across Asia, Latin America, Europe, the Middle East, and Africa. The company offers a diverse portfolio including life insurance, disability and accident coverage, dental and vision plans, annuities, retirement products, and corporate income solutions.
In the U.S., MetLife is organized around Group Benefits, which serves employers and employees with health and welfare benefits, and Retirement and Income Solutions, which provides retirement risk transfer, structured settlements, stable value, and other institutional retirement needs. These segments collectively form a substantial portion of the company's earnings base, linking it to demand for workplace benefits and corporate pension funding activities.
Internationally, MetLife maintains strong positions in markets such as Japan, Mexico, and Chile, providing exposure to various savings, protection, and demographic trends while navigating currency, regulatory, and macroeconomic complexities. The company also reports MetLife Holdings, which includes closed-block or run-off products that are no longer actively sold but continue to impact earnings and capital management.
Investors evaluate MetLife primarily through underwriting performance, investment income, interest rates, capital returns, and the resilience of demand for protection and retirement products. The business model relies on effectively pricing risk, managing a large investment portfolio, and maintaining financial strength throughout economic cycles.
🏢 MetLife operates globally with major U.S. life insurance and benefits divisions.
🇺🇸 Group Benefits serves employers while Retirement Solutions handles institutional needs.
🌍 Strong international positions in Asia, Latin America, Europe, Middle East, and Africa.
💼 Holdings include closed-block products impacting earnings and capital management.
🏢 MetLife is one of the world's largest life insurance and employee benefits companies with significant U.S. operations and a broad international footprint.
🇺🇸 In the U.S., Group Benefits serves employers and employees while Retirement and Income Solutions focuses on institutional retirement needs like stable value and structured settlements.
🌍 MetLife holds strong positions in Asia (especially Japan), Latin America (Mexico, Chile), Europe, the Middle East, and Africa, diversifying revenue streams across global markets.
💼 The company reports MetLife Holdings, which includes closed-block or run-off products that continue to impact earnings and capital management despite not being actively sold.
📈 Analyst sentiment remains strongly positive with 77% of analysts rating MetLife a Buy, indicating confidence in the company's long-term prospects.
📊 Technical indicators show the stock price is above both the 50-day and 200-day moving averages, suggesting a strong long-term upward trend.
Bullish Signals
77% of analysts rate MetLife as Buy.
Stock trades above 50-day and 200-day moving averages.
Analyst sentiment remains strongly positive with 77% of analysts rating MetLife a Buy, indicating broad institutional confidence in the company's strategic direction.
Technical indicators show the stock price is trading above both the 50-day and 200-day moving averages, confirming a strong long-term bullish trend.
Risk Factors
MACD momentum is weakening, suggesting potential short-term consolidation or pullback despite the strong long-term uptrend.
RSI is currently neutral, indicating that the stock may be approaching overbought conditions or lacks immediate explosive upward momentum.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)